---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-225369"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2026-05-15T12:03:20+00:00"
generated_at: "2026-05-15T12:05:31.805444+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MiNK Q1 cash $9.5M, net loss $2.7M; initiates randomized Phase 2 for agenT-797 in ARDS

## Summary
- Cash $9.5M at Mar 31 (down from $13.4M at Dec 31); repaid $5.2M Agenus convertible note.
- Net loss $2.7M ($0.57/sh) vs $2.8M ($0.70/sh) year ago; raised $3.0M via ATM in Q1.
- Initiated randomized Phase 2 trial of agenT-797 in severe acute lung injury/ARDS; data expected H2 2026.
- Non-dilutive C-Further collaboration provides up to $1.1M for PRAME-targeted iNKT therapy in pediatric cancers.
- Upcoming ATS presentation May 20 on agenT-797 for coccidioides infection; NIH-funded GvHD program ongoing.

## SEC filing metadata
- accession: 0001193125-26-225369
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2026-05-15T12:03:20+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000119312526225369/0001193125-26-225369-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000119312526225369/inkt-20260515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-225369
- JSON: https://secwatch.observer/filing/0001193125-26-225369.json
- Plain text: https://secwatch.observer/filing/0001193125-26-225369.txt

## Key facts
- Earnings Releases
  MiNK Therapeutics, Inc. reported financial results for the first quarter ending March 31, 2026.
  - Period: the first quarter ending March 31, 2026
  - Result: reported results
  source text: On May 15, 2026, MiNK Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840229/000119312526225369/0001193125-26-225369-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.